All Stories

AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustat

AstraZeneca is paying $160 million for FibroGen’s Chinese business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat.

Feb 20, 2025 - 15:17
 0
AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustat
AstraZeneca is paying $160 million for FibroGen’s Chinese business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat.
Read More

Tags:

Previous Article

Trucking braces for immigration crackdowns

Next Article

FDA hits pair of Indian API makers with warning letters, import alerts

Related Posts

Regulatory tracker: Novartis, Valneva pick up new UK approvals

Regulatory tracker: Novartis, Valneva pick up new UK ap...

Feb 9, 2025  0

Moderna trims digital team, lays off employees as chief information officer departs

Moderna trims digital team, lays off employees as chief...

Feb 13, 2025  0

Alnylam touts Amvuttra's potential move into ATTR-CM as a 'market-growth story'

Alnylam touts Amvuttra's potential move into ATTR-CM as...

Feb 13, 2025  0